Cantor Fitzgerald analyst Josh Schimmer reiterated an Overweight rating on Aardvark Therapeutics Inc (NASDAQ: AARD).The analyst commented, "AARD reported 4Q ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE